These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19566120)

  • 1. Blasting neuroblastoma using optimal control of chemotherapy.
    Collins C; Fister KR; Key B; Williams M
    Math Biosci Eng; 2009 Jul; 6(3):451-67. PubMed ID: 19566120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
    Panetta JC; Schaiquevich P; Santana VM; Stewart CF
    Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
    Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
    J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil dynamics after chemotherapy and G-CSF: the role of pharmacokinetics in shaping the response.
    Brooks G; Provencher G; Lei J; Mackey MC
    J Theor Biol; 2012 Dec; 315():97-109. PubMed ID: 22981924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
    Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB
    Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis.
    Kramer K; Kushner BH; Cheung NK
    J Pediatr Hematol Oncol; 2003 Aug; 25(8):601-5. PubMed ID: 12902911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of phase I clinical studies with topotecan.
    Rowinsky EK; Verweij J
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
    Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
    Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
    J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
    Kushner BH; Kramer K; Modak S; Cheung NK
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):84-7. PubMed ID: 14734455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
    Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
    Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan.
    Chappell MJ; Evans ND; Errington RJ; Khan IA; Campbell L; Ali R; Godfrey KR; Smith PJ
    Comput Methods Programs Biomed; 2008 Feb; 89(2):169-78. PubMed ID: 18082908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based models for topotecan-induced neutropenia.
    Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
    Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Kretschmar CS; Kletzel M; Murray K; Thorner P; Joshi V; Marcus R; Smith EI; London WB; Castleberry R
    J Clin Oncol; 2004 Oct; 22(20):4119-26. PubMed ID: 15483021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan.
    Evans ND; Errington RJ; Shelley M; Feeney GP; Chapman MJ; Godfrey KR; Smith PJ; Chappell MJ
    Math Biosci; 2004 Jun; 189(2):185-217. PubMed ID: 15094319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
    McCluskey AG; Boyd M; Gaze MN; Mairs RJ
    Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.